In the AR+ prostate cancer cell line LNCaP, siRNA-mediated knockdown of TRPM8 or using a chemical blocker of TRPM8 (capsazepine) reduced cell viability (by MTT assay) and induced apoptotic nuclei [36]. Here, AR is linked to prostate carcinoma.